There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Crinetics Pharmaceuticals (CRNX – Research Report), Wave Life Sciences (WVE – Research Report) and Intellia Therapeutics (NTLA – Research Report) with bullish sentiments.
Crinetics Pharmaceuticals (CRNX)
Robert W. Baird analyst Brian Skorney maintained a Buy rating on Crinetics Pharmaceuticals on May 9 and set a price target of $52.00. The company’s shares closed last Monday at $47.93, close to its 52-week high of $51.29.
According to TipRanks.com, Skorney is a 2-star analyst with an average return of
Crinetics Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $64.36, representing a 33.6% upside. In a report issued on May 10, LifeSci Capital also maintained a Buy rating on the stock with a $69.00 price target.
See today’s best-performing stocks on TipRanks >>
Wave Life Sciences (WVE)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Wave Life Sciences on May 9 and set a price target of $12.00. The company’s shares closed last Monday at $5.69.
According to TipRanks.com, Schwartz is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Wave Life Sciences with a $12.20 average price target, an 113.3% upside from current levels. In a report issued on April 30, Mizuho Securities also maintained a Buy rating on the stock with a $19.00 price target.
Intellia Therapeutics (NTLA)
In a report issued on May 9, Mani Foroohar from Leerink Partners reiterated a Buy rating on Intellia Therapeutics, with a price target of $70.00. The company’s shares closed last Monday at $25.42.
According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $62.79, a 151.1% upside from current levels. In a report issued on May 9, RBC Capital also maintained a Buy rating on the stock with a $60.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRNX:
- Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics price target raised to $70 from $68 at Citi
- Crinetics reports Q1 EPS (93c), consensus (81c)
- Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Crinetics Pharmaceuticals Showcases Research at ENDO 2024
